Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dabigatran dose 2 Clear all
Terminated Phase 2 Interventional Results available

Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048

NCT00157248
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
12
States / cities
La Mesa, California • Pensacola, Florida • Port Charlotte, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 3 Interventional Results available

Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

NCT02197416
View directory record Official record
Conditions
Venous Thromboembolism, Secondary Prevention
Interventions
dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Up to 18 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
9
States / cities
Sacramento, California • Miami, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

NCT02164864
View directory record Official record
Conditions
Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions
Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin, Dabigatran Etexilate 150mg, Clopidogrel or Ticagrelor, Warfarin 5mg, Warfarin 1mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
45
States / cities
Birmingham, Alabama • Cottonwood, Arizona • Mesa, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

NCT03539055
View directory record Official record
Conditions
Atrial Fibrillation, Device Related Thrombus, Left Atrial Appendage Thrombosis, Watchman LAA Closure Device
Interventions
Dabigatran Etexilate Oral Capsule
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Bosutinib And Dabigatran

NCT02102633
View directory record Official record
Conditions
Healthy
Interventions
Dabigatran, Bosutinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 3 Interventional Results available

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

NCT00808067
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
dabigatran dose 1, dabigatran dose 2
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5,897 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
216
States / cities
Birmingham, Alabama • Mobile, Alabama • Lake Havasu City, Arizona + 185 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

NCT00262600
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
warfarin, Dabigatran dose 1, Dabigatran dose 2
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
18,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
374
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 286 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

NCT05347979
View directory record Official record
Conditions
Cushing Syndrome, Neoplasms
Interventions
Dabigatran Etexilate, Relacorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants

NCT04782076
View directory record Official record
Conditions
Healthy
Interventions
Dabigatran, Selpercatinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 3 Interventional Results available

Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement

NCT00152971
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Thromboembolism
Interventions
Dabigatran Dose 1 - day 2 to completion, Dabigatran Dose 1 - day 1, Dabigatran Dose 2 - day 2 to completion, Dabigatran Dose 2 - day 1, Enoxaparin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
59
States / cities
Birmingham, Alabama • Northport, Alabama • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 30, 2026, 3:44 PM EDT
Completed No phase listed Observational

Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients

NCT01727427
View directory record Official record
Conditions
Unsuspected Pulmonary Embolism
Interventions
Heparin, fondaparinux, vitamin-K antagonists, aspirin
Drug
Lead sponsor
G. d'Annunzio University
Other
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

NCT05064800
View directory record Official record
Conditions
Healthy Participants
Interventions
Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

NCT05334108
View directory record Official record
Conditions
Drug Interaction
Interventions
Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate, Cohort 3 Probe Substrate Cocktail
Drug · Combination Product
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 3 Interventional Results available

Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants

NCT01511939
View directory record Official record
Conditions
Osteoarthritis of the Knee, Coagulopathy
Interventions
Pennsaid
Drug
Lead sponsor
Nathan Wei, MD, FACP, FACR:
Other
Eligibility
55 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 30, 2026, 3:44 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

NCT05788328
View directory record Official record
Conditions
Healthy
Interventions
Dabigatran etexilate (DE), Rosuvastatin, PF-07081532
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 4 Interventional Results available

DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation

NCT02666742
View directory record Official record
Conditions
Ventricular Tachycardia, Premature Ventricular Contraction, Stroke
Interventions
DOAC, Aspirin
Drug
Lead sponsor
Kansas City Heart Rhythm Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Kansas City, Kansas • Overland Park, Kansas • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants

NCT02945020
View directory record Official record
Conditions
Healthy
Interventions
Dabigatran etexilate mesylate, Odalasvir (ODV), Simeprevir (SMV)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

NCT04809818
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
LT3001 drug product, Placebo, Aspirin, Clopidogrel, Apixaban, Dabigatran
Drug
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 30, 2026, 3:44 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants

NCT07629999
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986533, Famotidine, Placebo, Dabigatran Etexilate, Rosuvastatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants

NCT04459585
View directory record Official record
Conditions
Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib
Interventions
Dabigatran Etexilate Mesylate, Quizartinib
Drug
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 2 Interventional Results available

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

NCT00621855
View directory record Official record
Conditions
Coronary Disease
Interventions
placebo, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 30, 2026, 3:44 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

NCT03947385
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Interventions
IDE196, Binimetinib, Crizotinib
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 4 Interventional Results available

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

NCT03061006
View directory record Official record
Conditions
Dementia, Cognition Disorders, Cerebral Ischemic Events
Interventions
Dabigatran Etexilate, Warfarin
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
65 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

NCT02568397
View directory record Official record
Conditions
Healthy
Interventions
Lanabecestat, Dabigatran etexilate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 30, 2026, 3:44 PM EDT